HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OCGN
Ocugen, Inc.
There isn't enough reported data to score OCGN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OCGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
OCGN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OCGN PE Valuation
OCGN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OCGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OCGN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over OCGN on earnings, with more consistent year-over-year improvement.
OCGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.20 | +$0.01 |
| Q2 2026 | -$0.26 | -$0.07 |
| Q1 2026 | -$0.24 | -$0.06 |
| Q4 2025 | -$0.23 | -$0.05 |
| Q3 2025 | -$0.21 | -$0.04 |
| Q2 2025 | -$0.19 | -$0.01 |
| Q1 2025 | -$0.18 | +$0.06 |
| Q4 2024 | -$0.18 | +$0.08 |
OCGN is still losing money, but less than at its worst: $0.20 per share over the past year, against $0.38 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OCGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over OCGN on profitability, with a higher operating margin.
OCGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2M | +11% |
| Q2 2026 | $1.5M | +8.4% |
| Q1 2026 | $1.5M | +3.5% |
| Q3 2025 | $1.8M | +54% |
| Q2 2025 | $1.4M | +20% |
| Q1 2025 | $1.5M | +46% |
| Q4 2024 | $764K | -46% |
OCGN's revenue is down over the past year, though its latest quarter was up: $2M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -910% | +96 points |
| Q2 2026 | -1105% | -100 points |
| Q1 2026 | -1164% | -185 points |
| Q3 2025 | -1006% | +161 points |
| Q2 2025 | -1005% | +349 points |
| Q1 2025 | -979% | +226 points |
| Q4 2024 | -1812% | -994 points |
| Q3 2024 | -1167% | N/A |
OCGN's operating margin was −910% last quarter, up 95 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OCGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
OCGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$2.9M |
| Q2 2026 | -$12.2M | -$1.4M |
| Q1 2026 | -$21.8M | -$2.4M |
| Q4 2025 | -$14M | -$3.6M |
| Q3 2025 | -$13M | -$1.2M |
| Q2 2025 | -$10.8M | -$349K |
| Q1 2025 | -$19.4M | -$6.4M |
| Q4 2024 | -$10.4M | +$3.6M |
OCGN has burned cash in almost every quarter: −$64M over the past year, against −$54M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OCGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OCGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +534K shares |
| 1 year | +8.6% | +26.9M shares |
| 3 years | +32% | +82.7M shares |
| 5 years | +71% | +140M shares |
| Available history | +545% | +287M shares |
OCGN has 339M diluted shares, up 8.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OCGN Net Leverage
OCGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OCGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 17.9 | Oversold |
OCGN's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OCGN PE vs Healthcare Sector
OCGN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OCGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.88 | 1.1% below |
| 20 week MA | $1.13 | 23% below |
| 50 week MA | $1.39 | 37% below |
| 100 week MA | $1.19 | 27% below |
| 200 week MA | $1.05 | 17% below |
OCGN is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OCGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $1.76 | +340% |
| 2021 | $1.76 | $5.30 | +201% |
| 2022 | $5.30 | $1.21 | -77% |
| 2023 | $1.21 | $0.57 | -53% |
| 2024 | $0.57 | $0.85 | +49% |
| 2025 | $0.85 | $1.41 | +66% |
| 2026 YTD | $1.41 | $0.87 | -38% |
OCGN has the edge over HIMS on returns for 2026, with the stronger performance.